Study to Assess the Injection Site Pain Associated With a New Etanercept Formulation in Adults With Rheumatoid Arthritis or Psoriatic Arthritis

Inclusion Criteria * Subject has provided informed consent prior to initiation of any study specific activities/procedures. * Male or female subject is 18 years of age or older at time of signing the informed consent form. * Subject has a diagnosis of RA or PsA and indicated for treatment with etanercept per the current label, based on investigator judgment. * Subject is naïve to etanercept. * Subject is able to self-inject etanercept. Exclusion Criteria * Subject is diagnosed with Felty's syndrome. * Subject has active erythrodermic, pustular, guttate psoriasis, or medication induced psoriasis, or other skin conditions. * Subject has a history of clinically significant skin allergies * Subject has a history of alcoholic hepatitis, nonalcoholic steatohepatitis or immunodeficiency syndromes. * Subject has any active infection for which anti-infectives were indicated within 4 weeks prior to screening. * Subject has had a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to first dose of investigational product. * Subject had prosthetic joint infection within 5 years of screening or native joint infection within 1 year of screening. * Subject has known alcohol addiction or dependency. * Subject has positive hepatitis B surface antigen, hepatitis B core antibody (confirmed by hepatitis B virus deoxyribonucleic acid (DNA) test) or hepatitis C virus antibody serology at screening, or a positive medical history for hepatitis B or C. (Subjects with a history of hepatitis B vaccination without history of hepatitis B are allowed to enroll). * Subject has any active malignancy, including evidence of cutaneous basal or squamous cell carcinoma or melanoma. * Subject has known history of active tuberculosis. * Subject has used biologic disease modifying agent (DMARD) less than or equal to 3 months prior to screening. * If subject is receiving continuous treatment with acetaminophen, non-steroidal anti-inflammatory drug or tramadol, hydrocodone, oxycodone, codeine, and/or propoxyphene and the dose is within 4 hours before study visit and dose is not stable for ≥ 2 weeks before first dose of investigational product * For subjects not on continuous analgesics, subject has taken the following within 4 hours before screening: acetaminophen, non-steroidal anti-inflammatory drugs, hydrocodone, codeine, tramadol, propoxyphene, and/or oxycodone (unless in the form of OxyContin). For subjects not on continuous analgesics, subject has taken OxyContin within 24 hours before screening. * Subject has received live vaccines less than or equal to 4 weeks prior to first dose of investigational product. * Subject has laboratory abnormalities during screening. * Estimated creatinine clearance less than 50 mL/min. * Subject has any other laboratory abnormality, which, in the opinion of the investigator poses a safety risk, will prevent the subject from completing the study, or will interfere with the interpretation of the study results. * Subject is currently receiving treatment in another investigational device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s). * Other investigational procedures while participating in this study. * Women who are pregnant or breastfeeding, or planning to become pregnant or breastfeed during treatment and/or within 4 weeks after the last dose of etanercept. * Women of child-bearing potential with a positive pregnancy test. * Women of child-bearing potential who are unwilling to practice true sexual abstinence or unwilling to use 1 of the following effective birth control methods during treatment and for an additional 4 weeks after the last dose of etanercept.